ARTICLE | Top Story

Cell Medica raises L50M series B

November 26, 2014 1:49 AM UTC

Cell therapy developer Cell Medica Ltd. (London, U.K.) raised L50 million ($78.2 million) in a series B round led by Imperial Innovations. Invesco Perpetual and Woodford Investment Management also participated.

Cell Medica's CMD-003 ( Cytorex EBV) is in a Phase II trial to treat advanced lymphoma associated with Epstein-Barr virus. CMD-003 is comprised of EBV-specific cytotoxic T lymphocytes (CTLs). ...